TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03608163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Naloxone Nasal Spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Naloxone Nasal Spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone
Description: Naloxone Nasal Spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazoxide
Description: Diazoxide (oral)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide
Description: Diazoxide (oral)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Naloxone)
Description: Sterile water nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Naloxone)
Description: Sterile water nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Naloxone)
Description: Sterile water nasal spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Diazoxide)
Description: Taste matched oral placebo for diazoxide
Study: NCT00483171

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CP-945,598
Description: CP-945,598

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Non-pharmacological weight loss program (NPP)
Description: Nutrition counseling, exercise monitoring and behavioral management will occur for all arms during the NPP.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Low Calorie Diet
Description: Low calorie diet
Study: NCT03608163

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Diazoxide)
Description: Taste matched oral placebo for diazoxide
Study: NCT02942017

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of matching placebo for SAGE-547.
Study: NCT01211613

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Manipulation
Description: Doctor of chiropractic will apply manual high-velocity low-amplitude thrust to lumbar spine of research participants.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanically-assisted manipulation
Description: Doctor of chiropractic will use the Activator Instrument to apply a mechanically-assisted thrust to the lumbar spine of research participants.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Care
Description: Patients will receive an examination with a physician who is board certified in physical medicine and rehabilitation. Treatment will consist of medical monitoring of the patient's condition over 4 weeks (baseline and 2 follow up exams) and a prescription for over-the-counter anti-inflammatory medications if indicated.
Study: NCT00357708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT00426218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885
Study: NCT00131573

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bion
Description: battery powered bion microstimulator

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: bion
Description: battery powered bion microstimulator
Study: NCT01396473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Policy and Environmental Change
Description: Afterschool programs participate in an assessment of physical activity and nutrition practices and policies. Study staff work with teams of afterschool programs in a participatory manner to identify areas in which programs would like to take practice, policy and communication efforts to meet physical activity and nutrition goals. Teams share progress and barriers during ongoing collaborative meetings.
Study: NCT00791154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: AMG 479 is administered to subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide is administered to subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide is administered to subjects

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etoposide
Description: Etoposide is administered to subjects

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered with Carboplatin and Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 102
Description: AMG 102 is administered to subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is administered to some subjects in combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is administered to some subjects in combination

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin is administered to some subjects in combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is administered to some subjects in combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is administered to some subjects in combination

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin is administered to some subjects in combination
Study: NCT02139930

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal Nicotine Control Group
Description: Participants will smoke experimental cigarettes for a period of 20-weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Nicotine Reduction Group
Description: Participants will smoke experimental cigarettes for a period of 20-weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gradual Nicotine Reduction Group
Description: Participants will smoke experimental cigarettes for a period of 20-weeks.
Study: NCT00352534

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: Undergo ultrasound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT05286983

Intervention type: BEHAVIORAL
Intervention: Family Centred Care (FCC) interventions as potentially better practices (PBPs)
Description: After the previous period, additional Family Centred Care (FCC) elements will be introduced gradually every 6 months, covering staff training, parent education, psychosocial support for families, and last but not least, the neonatal intensive care unit environment.~The focus group consisting of nurses and healthcare professionals will meet regularly and will decide on new FCC interventions as potentially better practices (PBPs). New additional PBPs will be disseminated into the greater team through workshops, hands-on teaching, displays, etc. Potential PBPs for our department enclose:~Parent participation on rounds Parent skill self-assessment Parent-to-parent support Regular staff education Improvement of psychosocial support Improvement of neonatal unit surroundings to promote parent-infant-closeness

Intervention type: BEHAVIORAL
Intervention: Family Centred Care (FCC) interventions as potentially better practices (PBPs)
Description: After the previous period, additional Family Centred Care (FCC) elements will be introduced gradually every 6 months, covering staff training, parent education, psychosocial support for families, and last but not least, the neonatal intensive care unit environment.~The focus group consisting of nurses and healthcare professionals will meet regularly and will decide on new FCC interventions as potentially better practices (PBPs). New additional PBPs will be disseminated into the greater team through workshops, hands-on teaching, displays, etc. Potential PBPs for our department enclose:~Parent participation on rounds Parent skill self-assessment Parent-to-parent support Regular staff education Improvement of psychosocial support Improvement of neonatal unit surroundings to promote parent-infant-closeness

Intervention type: BEHAVIORAL
Intervention: Family Centred Care (FCC) interventions as potentially better practices (PBPs)
Description: After the previous period, additional Family Centred Care (FCC) elements will be introduced gradually every 6 months, covering staff training, parent education, psychosocial support for families, and last but not least, the neonatal intensive care unit environment.~The focus group consisting of nurses and healthcare professionals will meet regularly and will decide on new FCC interventions as potentially better practices (PBPs). New additional PBPs will be disseminated into the greater team through workshops, hands-on teaching, displays, etc. Potential PBPs for our department enclose:~Parent participation on rounds Parent skill self-assessment Parent-to-parent support Regular staff education Improvement of psychosocial support Improvement of neonatal unit surroundings to promote parent-infant-closeness
Study: NCT03981614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO
Study: NCT02942017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-547 90 μg/kg/h
Description: Intravenous infusion of SAGE-547
Study: NCT03074578

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Watching Video-clip 1
Description: Video -clip 1 contains violent images and text

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Watching Video-clip 1
Description: Video -clip 1 contains violent images and text

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Watching Video-clip 2
Description: Video -clip 2 contains neutral images and text
Study: NCT03981614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine and Tipiracil Hydrochloride
Description: Given PO
Study: NCT00352534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT02721212

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Armeo Spring
Description: All patients of experimental group were treated according to an established protocol for ARMEO Spring. In the first session the device was adjusted for patients arms. The physiotherapist controlled functional space of upper limb movement and correct position of working station.~Each training session consisted of two parts with 30 minutes per session with Armeo Spring and 30 minutes per session with conventional treatment 5 days per week, for 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Rehabilitation
Description: The conventional treatment, under control of physiotherapist, consists of passive and active assisted mobilization of the upper limbs traditional training based on the Bobath concept (neuromuscular facilitation, postural control and proprioception exercises, verticalization and gait training).~Each training session consisted of 60 minutes with conventional treatment 5 days per week, for 6 weeks in a control group.~The conventional session in the experimental group lasted 30 minutes with the same techniques and methods.
Study: NCT04002752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-73763989
Description: Participants will receive JNJ-73763989 as single subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-73763989
Description: Participants will receive JNJ-73763989 as single subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-73763989
Description: Participants will receive JNJ-73763989 as single subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matching to JNJ-73763989 as single subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matching to JNJ-73763989 as single subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matching to JNJ-73763989 as single subcutaneous injection.
Study: NCT02193620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHN131 soft capsule with Nalbuphine HCl 60 mg/cap
Description: Multiple dose of oral PHN131 soft capsule with Nalbuphine HCl 60 mg/cap, initial dose : 120 mg ( 2 capsules), then 60 mg (1 capsule); t.i.d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo soft capsules
Description: Multiple dose of oral Placebo soft capsules, initial dose: 2 capsules, then 1 capsule; t.i.d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dicofenac
Description: All subjects will receive diclofenac by IM injection for analgesia as rescue pain control.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dicofenac
Description: All subjects will receive diclofenac by IM injection for analgesia as rescue pain control.
Study: NCT02580149

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Subjects will receive an oral loading dose of 180 mg ticagrelor on study day~1 followed by a maintenance dose of 90 mg twice daily for 14 days (until study day 15).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Subjects will receive a loading dose of 600 mg clopidogrel on the first study day followed by a maintenance dose of 75 mg once daily for 14 days
Study: NCT00765115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY450139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY450139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY450139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT02136173

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heliosphere bag (air filled balloon)
Description: sequential balloons . Heliosphere bag (air filled balloon)
Study: NCT02991209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study: NCT02761564

Intervention type: OTHER
Group type: OTHER
Intervention: Red blood cell tranfusion
Description: Red blood cell transfusion according to transfusion guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ScvO2 measure
Description: ScvO2 (oximetry) is measured at the distal lumen of the central venous catheter placed in the superior vena cava. Transfusion is performed if ScvO2 is inferior or equal to 65%.
Study: NCT04173221

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sublingual SDF-Measurement with communication and interpreting checklist to the treating physician
Description: Sublingual SDF-Measurement at admission and after 24h, with communication and interpreting checklist to the treating physician

Intervention type: OTHER
Group type: OTHER
Intervention: Sublingual SDF-Measurement without communication and interpreting checklist to the treating physician
Description: Sublingual SDF-Measurement at admission and after 24h, without communication and interpreting checklist to the treating physician
Study: NCT02670993

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Singing sessions.
Description: Patients will be in singing work groups, and will participate to these sessions during 12 weeks, with one session per week of 2 hours.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Painting sessions.
Description: Patients will be in painting groups, they will participate to this work session during 12 weeks, with one session of 2 hours per week.
Study: NCT02308865

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multi disciplinary palliative care monthly consultations
Description: multi disciplinary palliative care consultations with a doctor, a nurse, a psychologist and posibility of a physical therapist and a worship person.The primary consultation within 3 weeks inclusion and then every month at the same time that consultations onco-respiratory
Study: NCT03074578

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Watching Video-clip 2
Description: Video -clip 2 contains neutral images and text
Study: NCT00920868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: dasatinib at 50 mg PO BID)
Study: NCT02348489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGI-110 (guadecitabine)
Description: Investigational medicinal product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment Choice
Description: Choice of one: cytarabine, decitabine, or azacitidine
Study: NCT00127608

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collection of clinical samples
Description: The following samples were obtained from each subject:~* Vesicle fluid (VF) and vesicle swabs (VS) from four vesicles (for a total of eight samples)~* Papule swabs (PS) from four papules~* Crusts from two lesions~* One throat swab (TS) Up to 15 samples were to be obtained for each subject, when possible. VFs, VSs, PSs, and crusts were either stored dry or in liquid medium. TS samples were stored in liquid medium.~After extraction of DNA, samples were tested for the presence of varicella virus using a Quantitative Polymerase Chain Reaction (Q-PCR) technique.
Study: NCT04268017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FeetMe Monitor
Description: For gait parameters' evaluation, the investigator asks the participant to move in a straight line over a 10-meter mat. The participant had to start the feet in line and then start walking at a comfortable speed. During this time, the investigator records the gait parameters from the FeetMe Monitor® and Gaitrite® system.~An operator asked the patient to repeat 3 trials. The same sequence was repeated by three other operators. The same measurement is done 7 days later.~A questionnaire is given to assess the ergonomics of the device
Study: NCT01639001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: 250 mg two times daily \[BID\], oral, on a continuous daily dosing schedule. Cycles are defined in 21 day periods.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed/Cisplatin
Description: Option 1: Pemetrexed/Cisplatin; Pemetrexed, 500 mg/m\^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Cisplatin, 75 mg/m\^2 will be administered by infusion after adequate hydration according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and cisplatin will be repeated every 3 weeks for a maximum of 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed/Carboplatin
Description: Option 2: Pemetrexed/Carboplatin. Pemetrexed, 500 mg/m\^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Carboplatin, at a dose calculated to produce an AUC of 5 or 6 mg.min/mL will be administered by infusion according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and carboplatin will be repeated every 3 weeks for a maximum of 6 cycles.
Study: NCT02866682

Intervention type: DRUG
Group type: OTHER
Intervention: Prograf
Description: Brand Drug for the duration of the study.

Intervention type: DRUG
Group type: OTHER
Intervention: Tacrolimus
Description: Generic
Study: NCT00315328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: Atropine 1% each weekend day in the sound eye

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patching
Description: Patching 2 hours per day

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Near activities
Description: near visual activities for at least one hour per day

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Near activities
Description: near visual activities for at least one hour per day
Study: NCT03022019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReNovaCell
Study: NCT01040546

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized education
Description: We conducted a randomized controlled trial to evaluate the effects of three types of weight control educational intervention programs. Obese subjects were randomly allocated into individualized health education group, group weight control education and mail-delivered health education group.Obese subjects who were randomly allocated into individualized health education group received consulting services provided by a doctor, nutritionist and fitness expert. The interventions were 12 sessions over 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Grouped education
Description: We conducted a randomized controlled trial to evaluate the effects of three types of weight control educational intervention programs. Obese subjects were randomly allocated into individualized health education group, group weight control education and mail-delivered health education group.Obese subjects who were randomly allocated into grouped health education group attended 12 sessions of group intervention over 6 months.
Study: NCT00609063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 80-mg atorvastatin capsules taken daily for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules taken daily for 6 months
Study: NCT01740284

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Grazax + Aerius

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Grazax + placebo
Study: NCT01381185

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 200mg qd, Clopidogrel 2x75mg qd
Description: According to 2 platelet monitoring assays HPR confirmation aspirin will be increased to 200mg qd, clopidogrel to 2x75mg qd. This treatment will be given for 30 days from index event (myocardial infarction)
Study: NCT04232202

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er:YAG and Nd:YAG lasers
Description: Extraction followed by Er:YAG laser degranulation, Nd:YAG laser disinfection, Er:YAG deepithelialization, Nd:YAG blood clot stabilization and photobiomodulation. The photobiomodulation step repeated on day 3, 5, and 7.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard extraction
Description: Standard extraction procedure
Study: NCT03352570

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COLOVAC
Description: The intervention consists in the placement of the Colovac device, during the colorectal surgery, Once the colorectal anastomosis has been completed as per standard care and the water-thightness of the anastomosis has been verified.